Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Indivior Pharmaceuticals has reported Notes Payables over the past 3 years, most recently at $3.0 million for Q4 2023.

  • Quarterly results put Notes Payables at $3.0 million for Q4 2023, changed 0.0% from a year ago — trailing twelve months through Dec 2023 was $3.0 million (changed 0.0% YoY), and the annual figure for FY2023 was $3.0 million, changed 0.0%.
  • Notes Payables for Q4 2023 was $3.0 million at Indivior Pharmaceuticals, roughly flat from $3.0 million in the prior quarter.
  • Over the last five years, Notes Payables for INDV hit a ceiling of $3.0 million in Q4 2021 and a floor of $3.0 million in Q4 2021.
  • Median Notes Payables over the past 3 years was $3.0 million (2021), compared with a mean of $3.0 million.
  • Peak annual rise in Notes Payables hit 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
  • Indivior Pharmaceuticals' Notes Payables stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023.
  • The last three reported values for Notes Payables were $3.0 million (Q4 2023), $3.0 million (Q4 2022), and $3.0 million (Q4 2021) per Business Quant data.